Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 120,238

Document Document Title
WO/2017/023361A1
The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in a...  
WO/2017/021319A1
The present invention deals with novel compounds which are reactivators of human acetylcholinesterase, pharmaceutical compositions comprising said compounds, and their use in the treatment of a nervous and/or respiratory failure due to i...  
WO/2017/021951A1
Provided are compositions which include N-methyl-d-aspartate receptor (NMDA-R) antagonists. Moreover, provided are methods for reducing the permeability of the blood- brain-barrier, in a patient, by administering to the patient, a compos...  
WO/2017/017363A1
The invention relates to a gaseous drug including xenon gas for use in treating impaired cholinergic synaptic transmission in humans. Impaired cholinergic synaptic transmission causes disease of the central nervous system of said humans,...  
WO/2017/018475A1
The present invention provides a preventive or therapeutic agent for diseases such as mood disorders, anxiety disorders, schizophrenia, autism spectrum disorders, and Alzheimer's disease, which involve group II metabotropic glutamate (mG...  
WO/2017/018336A1
The present invention addresses the problem of providing a safe antinflammatory agent that is efficacious for ameliorating and improving inflammatory symptoms and for preventing and treating inflammatory diseases and has little side effe...  
WO/2017/017186A1
The present invention relates to a compound selected from 5-hydroxymethyl-2-furfural (5HMF), a prodrug thereof, a derivative thereof, and a metabolite thereof, said derivative being capable of enhancing the affinity of hemoglobin to oxyg...  
WO/2017/020005A1
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disord...  
WO/2017/018321A1
Provided is a method for manufacturing a patch that comprises a support and an adhesive layer laminated on the support, said method comprising: a step for mixing an acid addition salt of asenapine with a (meth)acrylic acid ester (co)poly...  
WO/2017/018322A1
The present invention provides an adhesive patch that is provided with a support body and an adhesive layer laminated upon one surface of the support body. The adhesive layer includes asenapine or a pharmaceutically acceptable salt there...  
WO/2017/020016A1
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disord...  
WO/2017/016668A1
The present invention relates to amide derivatives having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions compr...  
WO/2017/020002A1
This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disord...  
WO/2017/016512A1
The present invention provides a crystalline form A of masitinib mesylate, a preparation method therefor and a medical use thereof. The hygroscopicity of crystalline form A is remarkably reduced. Therefore, it is convenient for medicamen...  
WO/2017/019532A1
Provided herein are methods of using cyclic pyranopterin monophosphate (cPMP) for the treatment of diseases or disorders in humans related to molybdenum cofactor deficiency (MoCD) type A wherein at least once per day the active ingredien...  
WO/2017/015774A1
The invention relates to a method for treating pain in mammals, in which pannexin function-inhibitor compounds, including carbenoxolone, probenecid and 10panx, are administered to an individual suffering from pain. The invention also rel...  
WO/2017/017452A1
The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by t...  
WO/2017/016880A1
The present invention relates to the use of a neurotoxin, especially botulinum toxin, for use as a medicament in the treatment of a personality disorder and/or a habit and impulse disorder and/or a conduct disorder, as well as to a metho...  
WO/2017/018495A1
In the present invention, a compound represented by formula (I) (where each symbol in the formula is the same as defined in the description) or a pharmaceutically acceptable salt thereof has excellent TRPA1 antagonist activity, and the c...  
WO/2017/016669A1
The present invention relates to substituted amide derivatives of formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the p-opioid receptor, to processes of preparation of such compounds, to pharmac...  
WO/2017/017453A1
The present invention provides a transdermal patch comprising: a drug-containing layer comprising (R)-dihydroetorphine, or a salt or a hydrate thereof, and a poly(meth)acrylate; and a backing layer.  
WO/2017/019616A1
Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agon...  
WO/2017/015049A1
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Ch...  
WO/2017/015349A1
A combination of a muscarinic receptor antagonist consisting of a M2-receptor antagonist and of a non-selective, peripheral anticholinergic agent, and optionally an anticholinesterase inhibitor, and use of the same for treatment of hypoc...  
WO/2017/013599A1
A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amoun...  
WO/2017/012579A1
Disclosed are substituted indole compounds and use methods and uses thereof. The present invention particularly relates to novel indole compounds and pharmaceutical compositions comprising the compounds, for inhibiting re-uptake of 5-hyd...  
WO/2017/014315A1
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...  
WO/2017/015491A1
A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition ...  
WO/2017/012502A1
The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceut...  
WO/2017/013492A1
The present disclosure provides compositions comprising 15-HEPE for use in treating and/or preventing cancer and neurological diseases in a subject in need thereof.  
WO/2017/012088A1
An extraction method for a bird's nest extract comprises: extracting a broken bird's nest aqueous solution for 30 minutes to 12 hours at the temperature of 30 to 60°C, and stirring and vacuumizing the solution at the same time; then adj...  
WO/2017/012576A1
Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for examp...  
WO/2017/012599A1
The present invention relates to 5-substituted-7-[4-(substituted)benzyl]amino-3- isopropylpyrazolo[4,3-d]pyrimidines of formula (I) which are effective inhibitors od cyclin- dependent kinases and exhibit strong anti-inflammatory properti...  
WO/2017/014162A1
The purpose of the present invention is to provide: an amyloid β fibril-decomposing agent which contains a naturally occurring substance as an active ingredient; a therapeutic or prophylactic agent for a disease associated with amyloid ...  
WO/2017/011863A1
The invention relates to disulfide-rich peptides derived from spider venom and their use, particularly as neuroprotective agents. The invention also relates to nucleic acid molecules encoding the peptides as well as constructs and host c...  
WO/2017/013496A1
The compound (-)-tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride ((-)-ANAVEX2-73, (-)A2-73, (-)AE 37) has been found to exhibit selectivity for sigma-1 (σ1) receptors and stronger agonist activity at the muscarinic...  
WO/2017/014170A1
Provided are: a heterocyclic compound which has an HDAC-inhibiting activity and is useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancer, central nervous system diseases including...  
WO/2017/013498A2
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO2016069801A8
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, ...  
WO2017011294A1
The invention provides methods of reducing the frequency of migraine onset in a migraineur, reducing migraine symptoms experienced by a migraineur, augmenting the effects of pharmaceutical intervention to reduce the frequency of migraine...  
WO2016205270A8
The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides vario...  
WO2017010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO2017010538A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...  
WO2017009852A1
A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocy...  
WO2017010133A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...  
WO2017008686A1
Provided is an adipose-derived stem cell in which a thromboxane A2 receptor (TP) is deactivated or inhibited and/or the activity of a calpain is deactivated or reduced, and/or the activity of a β-catenin is enhanced. Also provided are a...  
WO2016170124A3
The present invention relates to the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.  
WO2016016380A8
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO2017009750A1
Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.  
WO2017009454A1
The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission ...  

Matches 51 - 100 out of 120,238